Retinoid X Receptor Alpha (RXRα; NR2B1)
|Product Family||Product Number||Product Description||Technical Manual|
|IB00801-32||Human RXRα Reporter Assay System, 3 x 32 assays in 96-well format||Technical Manual|
|IB00801||Human RXRα Reporter Assay System, 1 x 96-well format assays||Technical Manual|
|IB00802||Human RXRα Reporter Assay System, 1 x 384-well format assays||Technical Manual|
Retinoid X Receptor Alpha Assay Kit
This Retinoid X Receptor Alpha (RXRα) assay kit is an all-inclusive firefly luciferase reporter assay system that includes, in addition to RXRα Reporter Cells, two optimized media for use during cell culture and (optionally) in diluting the test samples, a reference agonist, Luciferase Detection Reagent, a cell culture-ready assay plate, and a detailed protocol.
RXRα Reporter Cells are prepared using INDIGO’s proprietary CryoMite™ process. This cryo-preservation method yields high cell viability post-thaw, and provides the convenience of immediately dispensing healthy, division-competent reporter cells into assay plates. There is no need for intermediate spin-and-wash steps, viability determinations, or cell titer adjustments.
INDIGO’s RXR alpha assay kits feature a luciferase detection reagent specially formulated to provide stable light emission between 5 and 90+ minutes after initiating the luciferase reaction. Incorporating a 5-minute reaction-rest period ensures that light emission profiles attain maximal stability, thereby allowing assay plates to be processed in batch. By doing so, the signal output from all sample wells, from one plate to the next, may be directly compared within an experimental set.
RXR alpha assay kits are offered in different assay formats to accommodate researchers’ needs: 3x 32, 1x 96, and 1x 384 assay formats for screening small numbers of test compounds, as well as custom bulk reagents for HTS applications.
Bulk assay reagents can be custom manufactured to accommodate any scale of HTS. Please inquire.
Retinoid X Receptor Alpha Assay Services
The primary application of INDIGO’s cell-based nuclear receptor assays are to quantitatively assess the bioactivity of a test compound as an agonist (activator) or antagonist (inhibition of an agonist response) of a given receptor. Service assays include a positive control reference compound and ‘vehicle’ control for every experiment. A formal study report and all data files are provided to the client upon completion of the study. To receive a quote for your proposed study, complete & submit the online “Request a Quote” form or contact an INDIGO Customer Service Representative to discuss your desired study parameters.
Retinoid X Receptor Alpha Background
Retinoid X receptor alpha (RXRα), also known as NR2B1 is a nuclear receptor which in humans is encoded by the RXRA gene. Retinoid X receptors (RXRs) and retinoic acid receptors (RARs), are nuclear receptors that mediate the biological effects of retinoids by their involvement in retinoic acid-mediated gene activation. These receptors exert their action by binding, as homodimers or heterodimers, to specific sequences in the promoters of target genes and regulating their transcription. The protein encoded by this gene is a member of the steroid and thyroid hormone receptor superfamily of transcription factors.
INDIGO’s RXR Alpha Reporter Assay System utilizes mammalian cells engineered to provide constitutive, high-level expression of Human Retinoid X Receptor Alpha (NR2B1), a ligand-dependent transcription factor commonly referred to as RXRA or RXRα. Additionally, these cells contain an RXRα-responsive luciferase reporter gene. Thus, quantifying luciferase activity provides a surrogate measure of RXRα activity in the treated reporter cells.
For more information on RXRα, visit the Nuclear Receptor Resource.
Synonyms: Retinoid X Receptor Alpha, RXRα, RXR Alpha, RXRa, Human Retinoid X Receptor Alpha, hRXRα, NR2B2
Retinoid X Receptor Alpha Assay Data
Agonist and Antagonist dose-response analyses of the Human RXRα. A.) Analyses of RXRα Reporter Cells using the reference agonists 9-cis-Retinoic Acid (provided). B.) Analyses of RXRα antagonist dose-responses using HX531 and UVI3003 (Tocris). Assay setups and quantification of RXRα activity were performed following the protocol provided in the assay Technical Manual. Luminescence was quantified and average relative light units (RLU) and corresponding standard deviation (SD) values were determined for each treatment concentration (n ≥ 4). Values of Fold-activation and Z’ were calculated as described by Zhang, et al. (1999). Non-linear regression and EC50 analyses were performed using GraphPad Prism software. High S/B and Z' scores confirm the robust performance of this RXRα Assay.